Company: NIVFW
Filing Date: 2025-05-30
Form Type: CORRESP
Source: 0001213900-25-049203
Chunk: 0

Company: NewGenIvf Group Ltd
Filing Date: 2025-05-30
Form: CORRESP
Chunk 0
---
May 30, 2025

VIA EDGAR

Robert Augustin

Katherine Bagley

Division of Corporation Finance

Office of Manufacturing

Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

| Re: | NewGenIvf Group Limited (CIK: 0001981662)                 
 Registration Statement on Form F-1 (File No. 333- 285629) |

Dear Mr. Augustin and Ms. Bagley:

In accordance with Rule 461
of the General Rules and Regulations under the Securities Act of 1933, as amended, NewGenIvf Group Limited (the “Company”)
hereby requests that the effectiveness of the above-referenced Registration Statement on Form F-1 (the “Registration Statement”)
be accelerated to and that the Registration Statement become effective at 4:30 p.m., Eastern Time, on June 3, 2025, or as soon thereafter
as practicable.

If there is any change in
the acceleration request set forth above, the Company will promptly notify you of the change, in which case the Company may be making
an oral request of acceleration of the effectiveness of the Registration Statements in accordance with Rule 461. The request may
be made by an executive officer of the Company or by any attorney from the Company’s U.S. counsel, Han Kun Law Offices LLP.

The Company understands that
the representatives of the underwriters of the offering, have joined in this request in a separate letter filed with the Securities and
Exchange Commission (the “Commission”) today.

The Company hereby acknowledges
the following:

| ● | should the Commission or the staff of the Commission (the                                                            
 “Staff”), acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission 
 from taking any action with respect to the filing;                                                                   |

| ● | the action of the Commission or the Staff, acting pursuant                                                                            
 to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy 
 and accuracy of the disclosure in the filing; and                                                                                     |

| ● | the Company may not assert Staff comments and the declaration                                                                             
 of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United 
 States.                                                                                                                                   |

<div align='center'>[Signature page follows]</div>

| Yours sincerely,        |                          |
| NewGenIvf Group Limited